TYK Medicines Past Earnings Performance
Past criteria checks 0/6
TYK Medicines's earnings have been declining at an average annual rate of -23.8%, while the Biotechs industry saw earnings growing at 15.4% annually. Revenues have been declining at an average rate of 100% per year.
Key information
-23.8%
Earnings growth rate
-7.7%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | -100.0% |
| Return on equity | n/a |
| Net Margin | n/a |
| Next Earnings Update | 30 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How TYK Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -407 | 71 | 259 |
| 31 Dec 23 | 0 | -382 | 59 | 249 |
| 31 Dec 22 | 44 | -311 | 34 | 230 |
Quality Earnings: 2410 is currently unprofitable.
Growing Profit Margin: 2410 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 2410's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 2410's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2410 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: 2410's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.